• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Chiesi Farmaceutici SpA - Product Pipeline Review - Q4 2010 Product Image

Chiesi Farmaceutici SpA - Product Pipeline Review - Q4 2010

  • Published: December 2010
  • Region: Global
  • 61 pages
  • Global Markets Direct

Chiesi Farmaceutici SpA – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Chiesi Farmaceutici SpA - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Chiesi Farmaceutici SpA - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Chiesi Farmaceutici SpA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination READ MORE >



List of Tables
List of Figures
Chiesi Farmaceutici SpA Snapshot
Chiesi Farmaceutici SpA Overview
Key Information
Key Facts
Chiesi Farmaceutici SpA – Research and Development Overview
Key Therapeutic Areas
Chiesi Farmaceutici SpA – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Chiesi Farmaceutici SpA – Pipeline Products Glance
Chiesi Farmaceutici SpA – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Chiesi Farmaceutici SpA Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Chiesi Farmaceutici SpA–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Chiesi Farmaceutici SpA – Drug Profiles
BDP + Salbutamol HFA pMDI
Product Description
Mechanism of Action
R&D Progress
CHF 1512
Product Description
Mechanism of Action
R&D Progress
CHF 2819
Product Description
Mechanism of Action
R&D Progress
CHF 4226
Product Description
Mechanism of Action
R&D Progress
CHF 5188
Product Description
Mechanism of Action
R&D Progress
Glycopyrrolate
Product Description
Mechanism of Action
R&D Progress
CHF4227
Product Description
Mechanism of Action
R&D Progress
CHF5074
Product Description
Mechanism of Action
R&D Progress
CHF 5633
Product Description
Mechanism of Action
R&D Progress
Chiesi Farmaceutici SpA – Pipeline Analysis
Chiesi Farmaceutici SpA – Pipeline Products by Therapeutic Class
Chiesi Farmaceutici SpA Pipeline Products By Target
Chiesi Farmaceutici SpA – Pipeline Products by Route of Administration
Chiesi Farmaceutici SpA – Pipeline Products by Molecule Type
Chiesi Farmaceutici SpA - Dormant Projects
Chiesi Farmaceutici SpA – Company Statement
Chiesi Farmaceutici SpA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Mar 10, 2009: Eurand Receives Orphan Drug Designation From FDA For EUR-1073 In Pediatric Patients
Financial Deals Landscape
Chiesi Farmaceutici SpA, Deals Volume Summary, 2004 to YTD 2010
Chiesi Farmaceutici SpA, Deals Summary By Region, 2004 to YTD 2010
Chiesi Farmaceutici SpA, Deals Summary, 2004 to YTD 2010
Chiesi Farmaceutici SpA Detailed Deal Summary
Acquisition
Chiesi Farmaceutici Acquires Stake In Cornerstone Therapeutics
Chiesi Farmaceutici Enters Into An Agreement With Iroko Pharmaceuticals
Chiesi Farmaceutici Enters Into Joint Venture With All Gen Pharmaceutical
Chiesi Farmaceutici Enters Into An Agreement With NiKem Research
Chiesi Farmaceutici Signs Agreement With 3M Drug Delivery Systems
Licensing Agreements
Phenomix Enters Into Licensing Agreement With Chiesi Farmaceutici
Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici
Nycomed International Management Enters Into Licensing Agreement With Chiesi Farmaceutici
Eurand Enters Into Licensing Agreement With Chiesi Farmaceutici
Chiesi Farmaceutici Enters Into Development And Licensing Agreement With SALVAT
Chiesi Farmaceutici Enters Into A Licensing Agreement With Novartis Pharma
Chiesi Farmaceutici Enters Into Licensing Agreement With GB Therapeutics
Chiesi Farmaceutici Enters Into Worldwide Licensing Agreement With GB Therapeutics
Chiesi Farmaceutici Enters Into A Licensing Agreement With Novartis Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS